Immunology
4 drugs are in development for Multiple Sclerosis.
- Companies
- 3
- Clinical trials
- 82
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Multiple Sclerosis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| bryostatin-1 | TAO Synergies Inc. (TAOX) |
Unknown(1)
| Drug | Company |
|---|---|
| peginterferon beta-1a | BIOGEN INC. (BIIB) |
Phase 4(2)
About this indication
Multiple Sclerosis context
Immunology·MeSH: Multiple Sclerosis (D009103)
Also known as: Disseminated Sclerosis, MS (Multiple Sclerosis)
Prevalence
120.0 / 100K
Incidence
7.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Multiple Sclerosis?
BioSniper tracks 4 drugs in development for Multiple Sclerosis across 3 companies.
How many clinical trials target Multiple Sclerosis?
There are 82 clinical trials targeting Multiple Sclerosis tracked by BioSniper.
What is the prevalence of Multiple Sclerosis?
The estimated prevalence of Multiple Sclerosis is approximately 120.0 per 100,000 population.